Farnesyl transferase inhibitors as anticancer agents

European Journal of Cancer

Volumn 38, Issue 13, 2002, Pages 1685-1700

  Haluska, P ^a   Dy, G K ^a   Adjei, A A ^a  

^a MAYO CLINIC   (United States)

Author keywords

BMS 214662; Farnesyl transferase inhibitors; R115777; Ras; Rho B; SCH66336; Signal transduction

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; CAPECITABINE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; L 778123; LONAFARNIB; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; TOPOTECAN; TRASTUZUMAB; 7-CYANO-2,3,4,5-TETRAHYDRO-1-(1H-IMIDAZOL-4-YLMETHYL)-3-(PHENYLMETHYL)-4-(2-THIENYLSULFONYL)-1H-1,4-BENZODIAZEPINE; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; IMIDAZOLE DERIVATIVE; L 778,123; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE; TRANSFERASE;

ABDOMINAL CRAMP; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFUSION; CYTOTOXICITY; DEHYDRATION; DIARRHEA; DRUG ACTIVITY; DRUG MECHANISM; DYSPNEA; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; SENSORY DYSFUNCTION; VOMITING; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; ONCOGENE RAS;

ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; CELL DIVISION; CLINICAL TRIALS; COMBINED MODALITY THERAPY; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GENES, RAS; HUMANS; IMIDAZOLES; NEOPLASMS; PIPERIDINES; PYRIDINES; QUINOLONES; TUMOR CELLS, CULTURED;

EID: 0035993192     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00166-1     Document Type: Article

References (129)

1. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity
2. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and-independent growth of human tumor cell lines
3. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956
4. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts
5. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines
6. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
7. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo
8. A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer
9. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial
10. Induction therapy with SCH 66336, a farnesyltransferase inhibitor, in squamous cell carcinoma (SCC) of the head and neck
11. A phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777+docetaxel: A promising combination in patients (PTS) with solid tumors
12. Phase I and pharmacologic study with the novel farnesyl transferase inhibitor (FTI) R115777
13. Use of farnesyl transferase inhibitor R115777 in relapsed and refractory acute leukemias: Preliminary results of a phase I trial
14. A phase I pharmacokinetic (PK) and biological study of the farnesyl transferase inhibitor (FTI) R115777 and capecitabine in patients (PTS) with advanced solid malignancies
15. A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
16. Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH66336 plus gemcitabine in advanced cancers
17. Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety
18. A phase I/II study of the farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in patients with solid tumors
19. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS
20. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes
21. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras- transformed rat embryo fibroblasts
22. Evidence for a catalytic role of zinc in protein farnesyltransferase. Spectroscopy of Co2+-farnesyltransferase indicates metal coordination of the substrate thiolate
23. Enzymatic modification of proteins with a geranylgeranyl isoprenoid
24. P21ras is modified by a farnesyl isoprenoid
25. Sequence dependence of protein isoprenylation
26. Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase
27. Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase
28. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides
29. CDNA cloning of the two subunits of human CAAX farnesyltransferase and chromosomal mapping of FNTA and FNTB loci and related sequences
30. Divalent cation and prenyl pyrophosphate specificities of the protein farnesyltransferase from rat brain, a zinc metalloenzyme
31. The prenylation of proteins
32. Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue
33. Tricyclic farnesyl protein transferase inhibitors: Crystallographic and calorimetric studies of structure-activity relationships
34. Posttranslational modification of proteins by isoprenoids in mammalian cells
35. A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins
36. Direct identification of palmitic acid as the lipid attached to p21ras
37. Blocking oncogenic Ras signaling for cancer therapy
38. Ras biochemistry and farnesyl transferase inhibitors: A literature survey
39. Farnesyltransferase inhibition causes morphological reversion of ras- transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
40. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
41. Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo
42. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine
43. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation
44. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1
45. CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB
46. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB
47. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity
48. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner
49. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation
50. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies
51. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: Important mechanistic and bench to bedside issues
52. Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli
53. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis
54. BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity
55. Dimerization properties of human BAD. Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-XL proteins
56. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
57. Specific regulation of CENP-E and kinetochores during meiosis I/meiosis II transition in pig oocytes
58. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells
59. The farnesyl transferase inhibitor SCH 66336 induces a G(2)→M or G(1) pause in sensitive human tumor cell lines
60. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway
61. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
62. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro
63. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
64. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of the farnesyl transferase inhibitor (FTI) R115777 in Japanese patients with advanced non-hematological malignancies
65. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors
66. Phase I trial of R115777, an oral farnesyltransferase (FTase) inhibitor, in children with refractory solid tumors and neurofibromatosis Type I (NF1)
67. A phase I and pharmacokinetic study of the farnesytransferase inhibitor, R115777 in combination with gemcitabine
68. Enhanced myelosuppression of topotecan when combined with the farnesyl transferase inhibitor, R115777: A phase I and pharmacodynamic study
69. Phase I trial of irinotecan in combination with the farnesyl transferase inhibitor (FTI) R115777
70. A phase I, pharmacokinetic, and biologic correlative study of R115777 and trastuzumab (herceptin) in patients with advanced cancer
71. Phase I trial of 5-FU/LV in combination with the farnesyltransferase inhibitor (FTI) R115777
72. Combination studies with the farnesyltransferase inhibitor R115777 and chemotherapy agents
73. Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells
74. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
75. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336
76. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336
77. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines
78. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo
79. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors
80. Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas
81. NCIC CTG IND.128: A phase II study of a farnesyl transferase inhibitor (SCH 66336) in patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract failing prior chemotherapy
82. Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)- 3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS- 214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity
83. Phase I trial of weekly paclitaxel and BMS214662 in patients with advanced solid tumors
84. Dose escalation study of oral farnesyl transferase inhibitor (FTI) BMS-214662 in patients with solid tumors
85. Phase I clinical trial of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors
86. Phase I study of farnesyl transferase inhibitor, BMS-214662 in solid tumors
87. A phase I pharmacokinetic (PK) and serial tumor and PBMC pharmacodynamic (PD) study of weekly BMS-214662, a farnesyltransferase (FT) inhibitor, in patients with advanced solid tumors
88. A phase I study of the farnesyltransferase (FT) inhibitor BMS-214662 administered as a weekly 1-hour infusion in patients (Pts) with advanced solid tumors: Clinical findings
89. A phase I dose escalating study of BMS-214662 in combination with cisplatin (C) in patients with advanced solid tumours
90. Phase I trial of the farnesyl protein transferase inhibitor L-778123 on a 14- or 28-day dosing schedule
91. A phase I and PK study of farnesyl transferase inhibitor L-778,123 administered as a seven day continuous infusion in combination with paclitaxel
92. Phase I trial of the farnesyl transferase inhibitor L-778123 in combination with radiotherapy
93. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation
94. Synergistic effect of the v-myc oncogene with H-ras on radioresistance
95. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts
96. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras
97. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes
98. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS
99. Phase I trial of the farnesyl transferase inhibitor L-778123 in combination with radiotherapy
100. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor
101. K-Ras-independent effects of the farnesyl transferase inhibitor L- 744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells
102. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
103. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
104. Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy
105. Protein prenylation: Molecular mechanisms and functional consequences
106. Posttranslational modification of the Ha-ras oncogene protein: Evidence for a third class of protein carboxyl methyltransferases
107. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues
108. Friends and family: The role of the Rab GTPases in vesicular traffic
109. Human lamin B contains a farnesylated cysteine residue
110. Rab geranylgeranyl transferase. A multisubunit enzyme that prenylates GTP-binding proteins terminating in Cys-X-Cys or Cys-Cys
111. A protein geranylgeranyltransferase from bovine brain: Implications for protein prenylation specificity
112. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors
113. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors
114. Farnesyltransferase inhibitors: Antineoplastic properties, mechanisms of action, and clinical prospects
115. Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases
116. PRL-1 PTPase expression is developmentally regulated with tissue-specific patterns in epithelial tissues
117. Prenyl group identification of rap2 proteins: A ras superfamily member other than ras that is farnesylated
118. Association of Rap1a and Rap1b proteins with late endocytic/phagocytic compartments and Rap2a with the Golgi complex
119. [Regulation of a small GTPase Rap2]
120. Characterization of HDJ-2, a human 40 kD heat shock protein
121. The farnesyl protein transferase (FPTase) inhibitor L-778,123 in patients with solid cancers
122. Human DnaJ homologs dj2 and dj3, and bag-1 are positive cochaperones of hsc70
123. The processing pathway of prelamin A
124. PxF, a prenylated protein of peroxisomes
125. Human adrenoleukodystrophy protein and related peroxisomal ABC transporters interact with the peroxisomal assembly protein PEX19p
126. In vivo differential prenylation of retinal cyclic GMP phosphodiesterase catalytic subunits
127. The gamma subunit of transducin is farnesylated
128. Isoprenylation of a protein kinase. Requirement of farnesylation/alpha- carboxyl methylation for full enzymatic activity of rhodopsin kinase
129. Farnesylcysteine, a constituent of the alpha and beta subunits of rabbit skeletal muscle phosphorylase kinase: Localization by conversion to S-ethylcysteine and by tandem mass spectrometry